Literature DB >> 15188027

Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients.

Sonali Ghosh1, Putul Maity.   

Abstract

Vascular Endothelial Growth Factor (VEGF) or Vascular Permeability Factor (VPF) is an angiogenic cytokine expressed by many human and animal tumors. Because of the importance of VEGF in animal tumors, we purified VEGF/VPF from ascitic fluid of ovarian cancer patients with heparin sepharose column. The purified protein gave protein bands of 37 and 26 kD, respectively in 12% SDS PAGE. The specificity of the purified protein was determined with dot blot, trans-immunoblot and ELISA using polyclonal goat anti-VEGF antibody (Santa Cruz Biotechnology). The vasodilatatory effect of the purified protein was confirmed by a vascular permeability assay on mouse. A polyclonal mouse antibody was raised against the purified protein, which recognized the same protein by ELISA, transimmunoblot and dot-blot analysis. It has been also found that the raised polyclonal antibody in mouse- and the commercial VEGF polyclonal antibody (Santa Cruz Biotechnology) both inhibited in vitrocell proliferation of human MCF-7 cell line. This study shows for the first time an effort to purify VEGF from human source.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188027     DOI: 10.1007/BF02893464

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   2.874


  19 in total

Review 1.  Vascular endothelial growth factor.

Authors:  N Ferrara
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

4.  The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

Authors:  Richard Béliveau; Denis Gingras; Erwin A Kruger; Sylvie Lamy; Pierre Sirois; Bryan Simard; Martin G Sirois; Leone Tranqui; Fabienne Baffert; Edith Beaulieu; Violetta Dimitriadou; Marie-Claude Pépin; Frank Courjal; Isabelle Ricard; Patrick Poyet; Pierre Falardeau; William D Figg; Eric Dupont
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

5.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

6.  Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

Authors:  J A Nagy; E M Masse; K T Herzberg; M S Meyers; K T Yeo; T K Yeo; T M Sioussat; H F Dvorak
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

7.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

8.  Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients.

Authors:  S Kondo; M Asano; K Matsuo; I Ohmori; H Suzuki
Journal:  Biochim Biophys Acta       Date:  1994-03-31

9.  Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.

Authors:  J C Luo; S Yamaguchi; A Shinkai; K Shitara; M Shibuya
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

10.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer.

Authors:  A Obermair; C Tempfer; L Hefler; O Preyer; A Kaider; R Zeillinger; S Leodolter; C Kainz
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  2 in total

1.  P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression.

Authors:  Chuan-Xiu Bian; Zhumei Shi; Qiao Meng; Yue Jiang; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Biochem Biophys Res Commun       Date:  2010-06-25       Impact factor: 3.575

2.  Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.

Authors:  Minghai Shao; Stacy Hollar; Daphne Chambliss; Jordan Schmitt; Robert Emerson; Bhadrani Chelladurai; Susan Perkins; Mircea Ivan; Daniela Matei
Journal:  Mol Cancer Ther       Date:  2012-06-13       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.